WO2001096388A3 - Compositions and methods for the therapy and diagnosis of colon cancer - Google Patents

Compositions and methods for the therapy and diagnosis of colon cancer Download PDF

Info

Publication number
WO2001096388A3
WO2001096388A3 PCT/US2001/018557 US0118557W WO0196388A3 WO 2001096388 A3 WO2001096388 A3 WO 2001096388A3 US 0118557 W US0118557 W US 0118557W WO 0196388 A3 WO0196388 A3 WO 0196388A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
therapy
protein
colon cancer
Prior art date
Application number
PCT/US2001/018557
Other languages
French (fr)
Other versions
WO2001096388A2 (en
WO2001096388A8 (en
Inventor
Yuqiu Jiang
Susan L Harlocker
Heather Secrist
Original Assignee
Corixa Corp
Yuqiu Jiang
Susan L Harlocker
Heather Secrist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Yuqiu Jiang, Susan L Harlocker, Heather Secrist filed Critical Corixa Corp
Priority to AU2001268259A priority Critical patent/AU2001268259A1/en
Priority to EP01946179A priority patent/EP1287028A2/en
Priority to JP2002510525A priority patent/JP2004512022A/en
Priority to CA002412223A priority patent/CA2412223A1/en
Publication of WO2001096388A2 publication Critical patent/WO2001096388A2/en
Publication of WO2001096388A8 publication Critical patent/WO2001096388A8/en
Publication of WO2001096388A3 publication Critical patent/WO2001096388A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.
PCT/US2001/018557 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer WO2001096388A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001268259A AU2001268259A1 (en) 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer
EP01946179A EP1287028A2 (en) 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer
JP2002510525A JP2004512022A (en) 2000-06-09 2001-06-08 Compositions and methods for treatment and diagnosis of colon cancer
CA002412223A CA2412223A1 (en) 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21089900P 2000-06-09 2000-06-09
US60/210,899 2000-06-09
US27021601P 2001-02-20 2001-02-20
US60/270,216 2001-02-20

Publications (3)

Publication Number Publication Date
WO2001096388A2 WO2001096388A2 (en) 2001-12-20
WO2001096388A8 WO2001096388A8 (en) 2002-03-21
WO2001096388A3 true WO2001096388A3 (en) 2002-10-03

Family

ID=26905617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018557 WO2001096388A2 (en) 2000-06-09 2001-06-08 Compositions and methods for the therapy and diagnosis of colon cancer

Country Status (6)

Country Link
US (1) US20020177552A1 (en)
EP (1) EP1287028A2 (en)
JP (1) JP2004512022A (en)
AU (1) AU2001268259A1 (en)
CA (1) CA2412223A1 (en)
WO (1) WO2001096388A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858386B1 (en) 1998-05-21 2005-02-22 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
EP2080802B1 (en) 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE69934903T2 (en) 1998-11-10 2007-10-18 Emory University MITOGENE REGULATORS
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
AU2001251668A1 (en) * 2000-04-18 2001-10-30 Millennium Pharmaceuticals, Inc. 39228, a human alcohol dehydrogenase and uses therefor
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
JP2004512023A (en) * 2000-06-09 2004-04-22 コリクサ　コーポレイション Compositions and methods for treatment and diagnosis of colon cancer
WO2002012332A2 (en) * 2000-08-07 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US6682890B2 (en) * 2000-08-17 2004-01-27 Protein Design Labs, Inc. Methods of diagnosing and determining prognosis of colorectal cancer
JP2005503116A (en) * 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Human G protein chemokine receptor (CCR5) HDGNR10
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121311A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in livestock
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2459318C (en) 2001-09-06 2017-09-26 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003268905A1 (en) * 2002-05-21 2003-12-02 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
EP1365242A1 (en) * 2002-05-21 2003-11-26 MTM Laboratories AG Compounds for detection and treatment of colorectal lesions
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
CA2508726A1 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
EP1579220B1 (en) 2002-12-20 2007-08-15 Roche Diagnostics GmbH Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20120122103A1 (en) 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
BRPI0413930A (en) 2003-09-18 2006-10-24 Isis Pharmaceuticals Inc oligomeric compound or pharmaceutically acceptable salt thereof, pharmaceutical or veterinary composition, methods for inhibiting eif4e expression in a cell, tissue or organ, for decreasing proliferation of a cell in which eif4e is expressed, and for preventing or treating a condition or disease. methods for preventing or decreasing angiogenesis, and tumor growth in a patient, antisense oligonucleotide, pharmaceutical or veterinary composition, and use of an oligomeric compound or pharmaceutically acceptable salt thereof.
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
GB0329997D0 (en) * 2003-12-24 2004-01-28 Cancer Rec Tech Ltd Methods for detecting neoplasia and markers thereof
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
AU2004319915B9 (en) 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP4810533B2 (en) 2004-05-24 2011-11-09 アイビス バイオサイエンシズ インコーポレイティッド Mass spectrometry using selective ion filtration by digital thresholding.
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
EP1869180B1 (en) 2005-03-03 2013-02-20 Ibis Biosciences, Inc. Compositions for use in identification of polyoma viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
AU2006272776B2 (en) 2005-07-21 2012-01-19 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
WO2007048978A2 (en) * 2005-10-28 2007-05-03 Biomerieux Sa Method for detecting cancer
DE102005059242A1 (en) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molecular markers for tumor diagnosis and therapy
JP5420412B2 (en) 2006-09-14 2014-02-19 アイビス バイオサイエンシズ インコーポレイティッド Targeted whole genome amplification method for pathogen identification
DK2502938T3 (en) 2006-10-27 2015-04-20 Genentech Inc Antibodies and immunoconjugates and uses thereof
WO2008104002A2 (en) 2007-02-23 2008-08-28 Ibis Biosciences, Inc. Methods for rapid forensic dna analysis
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
WO2010033625A1 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
WO2010033627A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
WO2010059575A2 (en) 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
WO2010093943A1 (en) 2009-02-12 2010-08-19 Ibis Biosciences, Inc. Ionization probe assemblies
EP2454000A4 (en) 2009-07-17 2016-08-10 Ibis Biosciences Inc Systems for bioagent identification
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
WO2011047307A1 (en) 2009-10-15 2011-04-21 Ibis Biosciences, Inc. Multiple displacement amplification
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
RU2019134462A (en) 2017-04-03 2021-05-05 Ф. Хоффманн-Ля Рош Аг ANTIBODIES BINDING WITH STEAP-1
MX2021008102A (en) 2019-09-03 2021-08-05 Sovargen Co Ltd Composition for diagnosing or treating conditions associated with increased elf4e activity comprising elf4e inhibitor.
KR102519920B1 (en) * 2020-12-29 2023-04-10 주식회사 메디케어텍 Cathether With Transformable Head Structure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326423A2 (en) * 1988-01-29 1989-08-02 Eli Lilly And Company Vectors, compounds and methods for expression of a hum adenocarcinoma antigen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326423A2 (en) * 1988-01-29 1989-08-02 Eli Lilly And Company Vectors, compounds and methods for expression of a hum adenocarcinoma antigen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PEREZ M S ET AL: "ISOLATION AND CHARACTERIZATION OF A CDNA ENCODING THE KS1/4 EPITHELIAL CARCINOMA MARKER", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 142, no. 10, 15 May 1989 (1989-05-15), pages 3662 - 3667, XP000651096, ISSN: 0022-1767 *
SIMON B ET AL: "EPITHELIAL GLYCOPROTEIN IS A MEMBER OF A FAMILY OF EPITHELIAL CELL SURFACE ANTIGENS HOMOLOGOUS TO NIDOGEN, A MATRIX ADHESION PROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, no. 7, 1 April 1990 (1990-04-01), pages 2755 - 2759, XP000651084, ISSN: 0027-8424 *
SZALA S ET AL: "MOLECULAR CLONING OF CDNA FOR THE CARCINOMA-ASSOCIATED ANTIGEN GA 733-2", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, no. 9, 1 May 1990 (1990-05-01), pages 3542 - 3546, XP000566331, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2001268259A1 (en) 2001-12-24
WO2001096388A2 (en) 2001-12-20
WO2001096388A8 (en) 2002-03-21
EP1287028A2 (en) 2003-03-05
US20020177552A1 (en) 2002-11-28
JP2004512022A (en) 2004-04-22
CA2412223A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
WO2001096388A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001075171A3 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001051513A3 (en) Ovarian tumor-associated sequences
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 51/2001 UNDER "PUBLISHED", ADD "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELYIN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 510525

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2412223

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001946179

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946179

Country of ref document: EP